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Introduction 
Elevated total plasma homocysteine (tHcy) levels are considered to be an independent risk 
factor for arteriosclerosis and stroke. Prospective studies, however, have shown no or only 
weak associations (1). This has raised the question whether the temporal sequence of sample 
collection and disease occurrence may have impacted the study results of case control studies, 
i.e. the timing of tHcy measurements relative to stroke onset is a factor to be considered in the 
interpretation of results. To collect data on the importance of the time point of plasma tHcy 
measurement after stroke, we compared tHcy levels of acute stroke with tHcy levels in the 
convalescent phase.  
 
Methods 
We recruited patients with clinically and radiologically proven acute stroke admitted to the 
Department of Neurology, University of Bonn, Germany. Patients with transitory ischemic 
attacks or lacunar ischemic stroke were excluded from the study. Patients with concomitant 
diseases or medications that alter tHcy, such as renal insufficiency or multivitamin therapy, 
were excluded. Fasting venous blood samples were collected for determination of total plasma 
tHcy levels within three days after stroke and during a follow up examination after at least six 
months. tHcy was determined by fully automated particle-enhanced immunonephelometry 
with a BN II System (Dade Behring). The reference value for this method is 5-10 µmol/l 
fasting tHcy. 
Differences between the time points of homocysteine plasma level measurement were 
calculated with the two-sided t-test for paired samples. A p-value of ≤0.05 was considered 
statistically significant. All patients gave written informed consent. The study was approved 
by the local ethical committees.  
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Results 
Twenty-two patients were included in the study (47% women, average age 47.9 ± 15.2 years). 
Fifteen patients were diagnosed with thromboembolic ischemic stroke, four with sinus venous 
thrombosis and stroke, and three with intracerebral hemorrhage. The tHcy levels measured 
within 1-3 days after stroke (12.3 ± 3.8μmol/l) were not significantly different from tHcy 
levels measured during follow-up (13.6 ± 3.5μmol/l; p=0.22; figure 1) for all 22 patients and 
when patients with sinus thrombosis and hemorrhagic stroke were excluded (not shown). 
 
Discussion 
This study does not support the hypothesis that tHcy levels are different in the first three days 
after stroke in comparison with the convalescent phase. The small sample size and the 
heterogeneity of our sample allow for random errors and replication of these data in a 
different and larger population is warranted. Other studies have reported significantly lower 
homocysteine levels immediately after a vascular event, but rising levels during the next 
seven days (2-4). Given the design of our study, we cannot provide information on tHcy 
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levels of days 3-7. In summary, the present data suggest that measurement of tHcy levels can 
be performed within the first three days after stroke or in the convalescent phase without 
relevant influence of the time point of measurement.  
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